Get a Sample
Schedule a Meeting
Get a Sample
Table Of Content
November 2023
The global antibody ELISA kits for tropical infectious disease market size accounted for USD 2.54 billion in 2025 and is forecasted to hit around USD 4.41 billion by 2034, representing a CAGR of 6.32% from 2025 to 2034. The Asia Pacific market size was estimated at USD 769.58 million in 2024 and is expanding at a CAGR of 6.51% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
The global antibody ELISA kits for tropical infectious disease market size was estimated at USD 2.39 billion in 2024 and is predicted to increase from USD 2.54 billion in 2025 to approximately USD 4.41 billion by 2034, expanding at a CAGR of 6.32% from 2025 to 2034. The market for antibody ELISA kits for tropical infectious diseases is witnessing increasing momentum, driven by public health investment at the global level, increased surveillance programs, and access to diagnostic tests thanks to more widely available and emerging technologies.
Artificial intelligence is making remarkable strides in enhancing the antibody ELISA kits for tropical infectious disease market. New AI-led platforms are enabling quick and accurate differentiation of illnesses such as dengue, malaria, and leptospirosis through the ability to assess clinical and serological data with a level of precision that gives them significant advantages.
Similarly, the AI4NTD consortium has utilized sophisticated AI tools to strengthen diagnostics and surveillance for neglected tropical diseases such as soil-transmitted helminthiases and schistosomiasis, included real-time data on disease monitoring that can operate even in limited-resource settings. Important, important developments: ELISA testing is moving in a defining direction; instead of traditional lab assays, ELISA testing has changed to a smarter and integrated diagnostic mode.
The Asia Pacific antibody ELISA kits for tropical infectious disease market size is evaluated at USD 817.58 million in 2025 and is projected to be worth around USD 1,446.48 million by 2034, growing at a CAGR of 6.51% from 2025 to 2034.
Why Is Asia Pacific the Most Dominant Region in 2024?
Asia Pacific led the antibody ELISA kits for tropical infectious disease market for tropical infectious diseases in 2024, largely driven by high disease burden, a tropical climate, and the developing need for scalable diagnostics. Countries in the region have experienced outbreaks of dengue, malaria, chikungunya, and Japanese encephalitis regularly. ELISA kits are reliable and affordable, so they have found their way into the early detection of tropical infectious diseases to manage outbreaks. Healthcare funding has risen, the public is more aware of infectious diseases, and an increase in local kit manufacturers has improved access to testing in urban and rural areas, creating ongoing demand in the region.
China has taken the lead with its public health infrastructure and investments, and domestic diagnostic manufacture. Under the “Healthy China 2030” initiative, the country has made a commitment to disease prevention; there is a bias toward early detection solutions, including ELISA kits. In having an extensive laboratory network and significant government funding committed to public health, there is capacity for the speedy distribution of testing solutions, particularly from China. As such, China is important in the proliferation of diagnostics across the Asia Pacific region.
Why Is the Middle East & Africa Projected to be the Fastest-Growing Region During the Forecast Period?
The Middle East & Africa is expected to be the fastest-growing region, mainly owing to the increasing prevalence of infectious diseases, including vector and parasitic infections. There is a heightened awareness about early diseases detection, increasing healthcare expenditure. Across the region, many countries have endemic outbreaks of malaria, leishmaniasis, schistosomiasis, and viral fevers. Additionally, the growing involvement from international health organizations, government action policies for rapid early detection of disease, and greater potential adoption of ELISA-based diagnostics wider spread in many countries have all been beneficial.
Saudi Arabia leads the region due to its strategic investment in diagnostic technology and disease surveillance. The government has improved laboratory capacity and implemented health screening programs across the country to address indigenous endemic and imported tropical infections. Saudi Arabia's strong investment in healthcare, state-of-the-art healthcare system, and increased vigilance of public health has driven demand for quality ELISA kits to locate endemic diseases, making it the leader for broader advancement in the region concerning disease diagnostics.
Antibody ELISA (Enzyme-Linked Immunosorbent Assay) kits for tropical infectious disease refer to in vitro diagnostic tools designed to detect host antibodies (IgG, IgM, or IgA) against specific pathogens responsible for tropical diseases. These kits are typically used in clinical laboratories, public health programs, research institutions, and point-of-care settings for serodiagnosis, epidemiological surveillance, and outbreak monitoring of tropical infections such as dengue, chikungunya, Zika, yellow fever, malaria, and others. ELISA-based antibody detection offers the benefits of high sensitivity, scalability, and early-phase diagnosis, especially in endemic regions with limited molecular testing infrastructure.
| Report Coverage | Details |
| Market Size by 2034 | USD 4.41 Billion |
| Market Size in 2025 | USD 2.54 Billion |
| Market Size in 2024 | USD 2.39 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 6.32% |
| Dominating Region | Asia Pacific |
| Fastest Growing Region | Middle East & Africa |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Disease Type, Antibody Type, Sample Type, Technology Platform, End User, Distribution Channel, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Climate-Related Increase in Vector-Borne Disease Outbreaks Drives Demand for Antibody ELISA Kits
The accelerated distribution of tropical infections, which has been given a major push by climate change and urbanization, highlights the growing demand for antibody ELISA kits. The CDC notes that vector‑borne diseases are responsible for over 17% of all infectious diseases globally and annually cause more than 700,000 deaths. Over the past two decades, more than 3.9 billion people in over 132 countries have been at risk of contracting dengue, with an estimated 96 million symptomatic cases and an estimated 40,000 deaths every year. (Source: https://www.who.int)
Furthermore, Oropouche virus has been appearing in recent outbreaks in South America, which is now also appearing in the U.S. and among travelers returning from South America to Europe. 4.6 million cases and 2,400 deaths were reported in the Americas in 2023, and then 13 million cases and 8,200 deaths were reported in 2024. More than 760,000 dengue cases have already been reported as of early March 2025, which represents an increase of 15% from the 5-year average up to March for dengue. All of this is to emphasize the increasing disease burden, which has widened in space and place, and calls for reliable serological tools, which are increasing in interest and adoption of antibody ELISA kits for accurate, scalable detection and surveillance. (Source: https://www.cdc.gov)
Cross-Reactivity and False Positives Threaten ELISA Kit Validity
Important limitations for antibody ELISA kits that investigate tropical infectious diseases are low specificity, resulting in false positives because of cross-reactivity among co-endemic pathogens. For example, commercially available cysticercosis antibody ELISA kits show very high rates of cross-reaction in samples from patients with cystic hydatid disease, as well as to hymenolepiasis sera, which jeopardizes diagnostic accuracy.
In geographic regions where multiple parasitic infections coexist, cross-reactivity like this will markedly reduce confidence in ELISA clinical diagnostic results and require additional confirmatory testing, like LLGP-EITB or Western blot, to establish validity, which adds time, complexity, and cost. The complexities with diagnostics hinder greater adoption, trust, and acceptance by health providers and policy makers; and this in turn slow market penetration of ELISA kits in tropical settings where precise and reliable serodiagnosis is a critical need.
Incorporation into National Surveillance Programs Advances ELISA Kit Use
The increasing inclusion of antibody ELISA kits in government-led disease surveillance programs has created an attractive opportunity for the tropical infectious disease diagnostics market. Countries like India, Indonesia, and Thailand in Southeast Asia began systematically including serological tests as part of their national control programs for dengue, chikungunya, and malaria under the ELISA platform in their national disease surveillance activities.
The integration into government-integrated national disease surveillance programs provides legitimacy to the ELISA platform as a reliable diagnostic tool. It also provides regulatory certainty for manufacturers, with guaranteed procurement of large volumes of diagnostic tests. Manufacturers can adjust their research and development plans and production plans according to the national health priorities, benefitting from a clearer regulatory pathway, improved demand forecasting, and greater collaboration with public health authorities. More broadly, embedding ELISA assays into systemic disease control programs helps reinforce the key role that ELISA assays can play in governments' targeted disease control strategies.
Why is Dengue the Dominant Disease Type Segment?
The dengue segment represented the largest disease in 2024, which is primarily due to the continual presence of dengue fever in tropical and subtropical populations that require early and accurate diagnostics. The delivery of results by the ELISA kits for dengue detection is rapid and highly sensitive, allowing trusted screening potential in both endemic and outbreak scenarios, and, where delivered as part of a routine public health surveillance program and diagnostic process, could greatly strength the segment.
The Zika virus segment is expected to have the fastest rate in the antibody ELISA kits for tropical infectious disease market. This projection is supported by raised awareness of the neurological complications of the viral disease and the implications for maternal-fetal health. Is development of an emphasis on outbreak preparedness, government, and international funding for reliable detection tools, and adoption of the diagnostic is influenced by the Zika virus. As tropical areas of the world continue to experience emergent vector-borne threats, pandemic preparedness, flexibility, scalability, and potential for decentralized testing, the biometric ELISA kit for Zika virus detection would be a useful technology.
Which Antibody Type Dominates the Market in 2024?
The IgM segment accounted for the largest share of the antibody ELISA kits for tropical infectious disease market in 2024, due to its integral role in the identification of early-stage infections. The detection of IgM antibodies by the ELISA (Enzyme-linked immunosorbent assay) task is often regarded as the first step for any tropical infectious disease, as the identification of IgM antibodies is vital to carry out early diagnostics and help contain outbreaks. Additionally, there are several varieties of IgM ELISA kits on the market that can be used both in a hospital setting and by public health officials, all of which have reliable uses to identify acute infections.
The IgG/IgM Combo segment is expected to grow at the fastest rate in the forecast period by offering complete detection of infections, like both recent (IgM) and past (IgG) infections, in one test. They have high accuracy and are a useful diagnostic test because they are convenient. Combo kits are especially useful to travel health clinics and are one of the best diagnostic methods moving forward in endemic areas.
Why is the Serum Dominates Sample Type Segment?
The serum segment was the leading product in the antibody ELISA kits for tropical infectious disease market in 2024, due in part to the long-established, standard use of serum in many antibody-based diagnostic tests. Serum provides the highest concentration of antibodies for reliable and accurate ELISA testing. There has been widespread acceptance of serum in clinical laboratories, easy processing, and it is compatible with most ELISA platforms. Serum is the preferred sample type in diagnosing many tropical infectious diseases, including dengue, chikungunya, and Zika.
The saliva segment is projected to continue to grow at a faster rate than any other segment during the period of forecast period. This is in part due to low invasiveness, easy collection process, and the requirement of less trained personnel and any specialized setting. Antibody ELISA kits are being developed and tested using saliva samples, and have appealing features and potential for mass screening. These antibody ELISA kits using saliva will have a low user burden and increasing accuracy, especially for point-of-care testing or decentralized use to better facilitate access and response time to infectious disease outbreaks.
Which Technology Platform Segment Dominates the Market in 2024?
In 2024, the indirect ELISA segment had the largest share of the antibody ELISA kits for tropical infectious disease market. The indirect ELISA platform is widely used because of its high sensitivity and ability to detect specific antibodies against different tropical infectious agents such as dengue, chikungunya, and malaria. The indirect ELISA also has the flexibility in detecting various classes of antibodies and is relatively inexpensive for large-scale screening. Indirect ELISA is also compatible with a variety of sample types and is reliably able to discriminate between active and past infections.
During the forecast period, the multiplex ELISA segment is expected to grow at the fastest rate. Multiplex ELISA refers to a technology that allows the simultaneous detection of multiple antibodies in a single assay. Thereby, multiplex ELISA provides a means of diagnosing co-infections or monitoring multiple tropical diseases. With an increasing demand for an integrated solution to laboratory diagnostics, and considering disease monitoring in lower-resource settings, multiplex ELISA is poised to become an increasingly valuable technology for both public health and research applications.
Which End User Dominates the Market in 2024?
The diagnostic laboratories segment dominated the antibody ELISA kits for tropical infectious disease market in 2024. These laboratories are often the first point of care for the diagnosis of tropical infectious diseases, especially in endemic areas. Laboratory-based testing for these diseases would be performed by the diagnostic laboratories due to their access to trained laboratory personnel, robust laboratory infrastructure, and protocols for ELISA-based testing for tropical infectious diseases such as dengue, chikungunya, and malaria.
The NGOs & international health organizations segment, on the other hand, is anticipated to grow at the fastest rate throughout the study period of the forecast. The NGOs & international health organizations are fundamental to disease surveillance, outbreak response, and public health screening (large-scale) in under-resourced and difficult-to-reach areas. Global health adoption of rapid, scalable diagnostic tools continues to gain traction.
Why Distributors/Wholesalers are the Most Dominant in the Distribution Channel?
The distributors/wholesalers segment accounted for the largest share of the antibody ELISA kits for tropical infectious disease market in 2024. The role of these intermediaries is critical to ensuring the widespread and timely provision of ELISA kits to enable their access across all health care settings, especially where the medical infrastructure may be fragmented. Their access to established supply distribution networks, bulk purchase capacity, and relationships with manufacturers and customers allows them to distribute antibody ELISA kits effectively to diagnostic labs, hospitals, and clinics.
The tenders/government supply contracts segment, in contrast, is expected to grow at the fastest rate during the forecast period due to an increase in government-led initiatives toward tropical disease control and an increase in preventive diagnostics. Public health programs and international funding support for mass screening campaigns in endemic regions are increasing the demand for bulk, tenders/contracts for the procurement of the antibody ELISA kits.
By Disease Type
By Antibody Type
By Sample Type
By Technology Platform
By End User
By Distribution Channel
By Region
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
November 2023
August 2025
May 2025
October 2024